Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8647673 | Multiple Sclerosis and Related Disorders | 2016 | 7 Pages |
Abstract
Practice effect significantly contributes to continuous improvement in SDMT performance during natalizumab treatment: to test cognition, a change in key is required. Practice effect is less pronounced in patients with advanced disease. Cognition remains stable even in patients with progressive disease during more than 2 years of natalizumab treatment indicated by scores corresponding to baseline after changing the key.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Malte Roar, Zsolt Illes, Tobias Sejbaek,